beta-MSH inhibits brain inflammation via MC3/4 receptors and impaired NF-κB signaling

被引:13
作者
Muceniece, R
Zvejniece, L
Kirjanova, O
Liepinsh, E
Krigere, L
Vilskersts, R
Baumane, L
Gordjusina, V
Kalvinsh, I
Wikberg, JES
Dambrova, M
机构
[1] Latvian State Univ, Fac Med, LV-1001 Riga, Latvia
[2] Latvian Inst Organ Synth, LV-1006 Riga, Latvia
[3] Uppsala Univ, BMC, Div Pharmacol, Dept Pharmaceut Biosci, S-75124 Uppsala, Sweden
关键词
MSH peptides; HS014; NO; iNOS; NF-kappa B;
D O I
10.1016/j.jneuroim.2005.07.024
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The anti-inflammatory effects of melanocortin peptides have been demonstrated in different inflammation models. This is the first report describing the molecular mechanisms for the beta-MSH-induced suppression of bacterial lipopolisaccharide (LPS)-caused brain inflammation. We found that beta-MSH suppresses LPS-induced nuclear translocation of the transcription factor NF-kappa B, and inhibits the expression of inducible nitric oxide synthase, and the following nitric oxide overproduction in the brain, in vivo. Moreover, administering the preferentially MC4 receptor selective antagonist HS014 blocked completely these effects, Suggesting a tentative MC4 receptor mediated mechanism of action for the beta-MSH. However, as HS014 shows quite low selectivity vis-A-vis the MC3 receptor, a role for the MC3 receptor cannot be excluded. In conclusion, our results show that beta-MSH is capable of inhibiting brain inflammation via activation of melanocortin receptors, of the subtypes 4 and/or 3. (C) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 38 条
[1]   ENDOGENOUS CYTOKINE ANTAGONISTS DURING MYOCARDIAL-ISCHEMIA AND THROMBOLYTIC THERAPY [J].
AIRAGHI, L ;
LETTINO, M ;
MANFREDI, MG ;
LIPTON, JM ;
CATANIA, A .
AMERICAN HEART JOURNAL, 1995, 130 (02) :204-211
[2]  
[Anonymous], 1979, A Stereotaxic Atlas of the Rat Brain
[3]   Increased synthesis of nitric oxide in rat brain cortex due to halogenated volatile anesthetics confirmed by EPR spectroscopy [J].
Baumane, L ;
Dzintare, M ;
Zvejniece, L ;
Meirena, D ;
Lauberte, L ;
Sile, V ;
Kalvinsh, I ;
Sjakste, N .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2002, 46 (04) :378-383
[4]   Targeting melanocortin receptors as a novel strategy to control inflammation [J].
Catania, A ;
Gatti, S ;
Colombo, G ;
Lipton, JM .
PHARMACOLOGICAL REVIEWS, 2004, 56 (01) :1-29
[5]  
Catania A, 2000, ANN NY ACAD SCI, V917, P227
[6]  
Catania Anna, 1994, Neuroimmunomodulation, V1, P321, DOI 10.1159/000097183
[7]   Nitric oxide production in SJL mice bearing the RcsX lymphoma: A model for in vivo toxicological evaluation of NO center dot [J].
Gal, A ;
Tamir, S ;
Tannenbaum, SR ;
Wogan, GN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11499-11503
[8]   Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis [J].
Getting, SJ ;
Christian, HC ;
Flower, RJ ;
Perretti, M .
ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2765-2775
[9]  
Getting SJ, 2000, DRUG NEWS PERSPECT, V13, P19
[10]  
Getting SJ, 1999, J IMMUNOL, V162, P7446